Novartis AG (NYSE:NVS) has signed an agreement with CureVac NV to produce its CVnCoV COVID -19 vaccine candidate. The deal will boost potential vaccine supply by around 250 million doses in 2021 and 2022. Novartis enters deal to produce 250 million doses of CureVac’s...
Novartis AG (NYSE:NVS) has signed a definitive agreement to acquire all outstanding capital stock of US-based neurosciences firm Cadent Therapeutics for around $770 million. Novartis to pay $210 million upfront for the acquisition of Cadent Once the companies close...
